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Abstract
Background: Although cancer survivors are known to be at greater risk of developing second primary cancer (SPC),
SPC incidence estimates in France are thus far lacking. We used a multivariate approach to compute these
estimates and analyzed the effect of patient characteristics (gender, age at diagnosis, first cancer site, year of
diagnosis and follow-up) on SPC risk.
Methods: Data from ten French population-based cancer registries were used to establish a cohort of all patients
diagnosed with a first cancer between 1989 and 2004 and followed up until December 31, 2007. The person-year
approach was used to estimate standardized incidence ratios (SIRs) and excess absolute risks (EARs) of metachronous
SPC. Multivariate Poisson regression models were then used to model SIRs and EARs separately by gender, adjusting for
age, year of diagnosis, follow-up and first cancer site.
Results: Among the 289,967 followed-up patients with a first primary cancer, 21,226 developed a SPC. The SIR was of
1.36 (95% CI, 1.35-1.38) and the EAR was of 39.4 excess cancers per 10,000 person-years (95% CI, 37.4-41.3). Among male
and female patients, multivariate analyses showed that age, year of diagnosis, follow-up and first cancer site were often
independently associated with SIRs and EARs. Moreover, the EAR of SPC remained elevated during patient follow-up.
Conclusions: French cancer survivors face a dramatically increased risk of SPC which is probably related to the high
rate of tobacco and alcohol consumption in France. Multivariate modeling of SPC risk will facilitate the construction of
a tailored prediction tool to optimize SPC prevention and early detection strategies.
Keywords: Neoplasms, Second primary, Risk assessment, Multivariate analysis, Registries, France
Background
Cancer survivors are at greater risk of developing second
primary cancer (SPC) as well as other diseases [1]. With
improvements of cancer survival due to more frequent
early detection and advances in cancer treatments, the
cancer survivor population continues to grow, reaching an
estimated 28.8 million 5-year survivors worldwide [2], sur-
passing one million in France [2], while the complete US
cancer prevalence was estimated to be 11.9 million in
2008 [3]. Although large population-based studies using
cancer registries data have been carried out in the US,
Italy, Sweden, Switzerland, Australia, England and Wales,
Denmark, Finland and Japan to assess the risk of SPC de-
tailed by site of first primary cancer [4-14], SPC incidence
estimates in France are thus far lacking.
Moreover, as recent research has highlighted the need to
better identify high-risk groups in order to target preventive
and interventional clinical strategies, improving knowledge
about SPC risks among cancer survivors has become an
even more topical issue [15]. In previous population-based
studies, even if patient characteristics such as gender, age at
diagnosis, first cancer site, year of diagnosis and follow-up
have been frequently pointed out to be associated with the
risk of SPC, the direct effect of each one of these factors on
the risk of SPC has not been assessed simultaneously. This
is a matter of concern, as clinicians may be misled while
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assessing SPC risk of their patients based upon only one of
the above-mentioned characteristics, for the simple reason
that these characteristics are rarely independent of each
other and that confounding is likely to occur. To address
this issue, a multivariate analysis of the effects of patient
characteristics on SPC risk is indispensable.
The objectives of this study were to compute first SPC
incidence estimates in France and to analyze the associ-
ation between patient characteristics and the risk of SPC,
using a multivariate approach.
Methods
Data source and management
Data from ten French population-based cancer regis-
tries participating in the K2-France nationwide study
were used to establish a population-based cohort of all
patients presenting with a first cancer diagnosed be-
tween 1989 and 2004, excluding non-melanoma skin
cancers. Included registries cover eight administrative
regions of France (Bas-Rhin, Calvados, Doubs, Hérault,
Isère, Manche, Somme and Tarn), which comprise six
million inhabitants, representing 9.6% of the metropol-
itan French population. These registries have achieved a
high degree of completeness of ascertainment and inci-
dence data are regularly included in the ‘Cancer Inci-
dence in Five Continents’ monograph series [16]. Since
data from these public registries are not publicly avail-
able, each registry granted individual permission to use
its data for the purposes of this study. The vital status of
all patients was updated to December 31, 2007. The
proportion of patients lost to follow-up (i.e. alive at
some date before December 31, 2007 and with no SPC)
was 3.36%.
A SPC was defined as the first subsequent primary can-
cer occurring at least two months (≥61 days) after a first
cancer. Extensions, recurrences or metastases were not
considered as a SPC according to the IACR rules for mul-
tiple primary cancers [17]. Computation of the person-
years at risk (PYR) for each individual began after two
months of follow-up, and ended at the date of SPC diag-
nosis, last known vital status, death or December 31, 2007,
whichever came first. Patients who developed a synchron-
ous second cancer (<61 days of follow-up) were excluded
from this analysis. Data from all available cancer registries
were used to determine tumor rank, including data about
cancer diagnosed before the 1989–2007 period. Third and
subsequent primary cancers were not considered as SPC.
Finally, tobacco or alcohol consumption and first cancer
treatments were not analyzed because detailed data about
these exposures were not available.
The 3rd edition of the International Classification of
Diseases for Oncology (ICD-O-3) was used to code inva-
sive tumors [18]. Cancer sites (e.g. head and neck) and
subsites (e.g. oral cavity) were defined in accordance with
topography and morphology codes used in the EURO-
CARE project [19]. We focused the analyses on the risk of
SPC occurring in a different subsite as the first primary
cancer.
Outcomes
The “standard” person-years approach to study SPC inci-
dence was used [4,20]. The number of observed SPC (O)
was compared to the number expected (E) if patients with
a first cancer had experienced the same cancer rates as the
general population without cancer. Therefore, E was com-
puted by multiplying patient PYRs (allocated by gender,
attained age, year of follow-up and first cancer region of
diagnosis) with corresponding first cancer incidence rates
estimated from the general population. Age-Period-Cohort
models, where age and cohort effects were modeled using
smoothing splines, were utilized to provide robust first can-
cer incidence rate estimates, especially for scarce sites of
cancer [21]. This enables a calculation of the observed to
expected ratio (O/E ratio), also called standardized inci-
dence ratio (SIR), which can be interpreted as the relative
risk of SPC among patients with a first cancer compared
with the general population without cancer. Another rele-
vant indicator provided by this method is the Excess Abso-
lute Rate, commonly called Excess Absolute Risk (EAR),
which is the absolute number of excess cancer cases per
PYR among cancer patients, obtained by subtracting the
expected incidence rate of cancer from the observed inci-
dence rate of SPC.
Analysis strategy
The first stage of the analysis was to provide univariate es-
timations of SIR and EAR values of SPC by gender, age,
year of diagnosis, follow-up and site of first primary cancer
(stratified by gender). Then, patient characteristics associ-
ated with the risk of SPC were explored, using multivariate
Poisson regression models described by Breslow and Day,
Dickman et al. and used recently in the field of SPC inci-
dence [20,22-25].
These models, as opposed to standard Cox regression
models, enable account to be taken in the analysis of the
number of expected cancers in the general population, and
thus a direct modeling of the SIR and the EAR. Ratios of
SIRs and ratios of EARs are provided by these models. For
example, a ratio of SIR of 1.5 for younger patients com-
pared to older patients means that the SIR is 50% higher
among younger patients compared to older ones. In other
words, the relative risk of SPC among young patients com-
pared to the general population (SIR) is 50% higher than
the relative risk of SPC presented by older patients. SIRs
and EARs were modeled separately by gender, adjusting
for age, year of first cancer diagnosis, follow-up and first
cancer site. Finally, estimates of SIR and EAR values by site
of first and second cancer were computed in order to point
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out which sites deserve special attention during follow-up
of cancer survivors.
Byar’s accurate approximation to the exact Poisson dis-
tribution was used to compute 95% confidence intervals
(95% CI) of SIR and EAR values [20]. With respect to
Poisson regression models, assumptions were made that
the risk of SPC was constant within each follow-up inter-
val, and that the risk of SPC for any two patient subgroups
was proportional over follow-up time. All analyses were




A total of 325,407 patients presented with a first cancer
between 1989 and 2004 within the area covered by the
cancer registries participating in the K2-France study.
During the first two months after first cancer diagnosis,
4,053 (1.2%) patients presented a synchronous SPC,
27,190 (8.4%) died without developing a SPC and 4,197
were lost to follow-up (1.3%). Among the remaining co-
hort of 289,967 patients, 55.5% were males and the mean
age at first cancer diagnosis was 64.2 years (SD 15.0). The
median follow-up time was 4.0 years.
Overall SPC risk, univariate estimates
The risk of SPC was increased in this cohort of cancer
survivors. With 21,226 patients (7.3%) presenting a SPC
occurring in a different subsite as the first primary can-
cer, compared to 15,555.59 expected on the basis of the
rates estimated from the overall population without can-
cer, the SIR was of 1.36 (95% CI, 1.35-1.38) and the EAR
was of 39.4 excess cancers per 10,000 PYR (95% CI,
37.4-41.3).
Univariate estimates of SPC risk differed greatly across
patient characteristics, as reported in Table 1. It is worth
noting that, despite similar SIR values among male and fe-
male patients, males presented more than twice the excess
risk of SPC compared with females (EAR of 58.6 versus
21.7), due to a higher expected cancer risk among males
in the general population. In a similar way, although
higher relative risks of SPC were reported among young
patients (SIR of 2.14 for ≤44 years-old patients), cancer
survivors facing the highest excess risk of SPC were those
who developed a first cancer in the age range 45 to 54
years (EAR = 55.8). Finally, the risk of SPC remained ele-
vated during follow-up, with SIR and EAR values of 1.37
and 42.0 for ≥10 years of follow-up, respectively.
Results presented in Table 2 show clearly that the risk
of SPC was closely tied to the first cancer site, and that
patients with a first tobacco and alcohol-related cancer
carried the highest increased risk of SPC. Indeed, male
patients carried the highest excess risks of SPC if they
were diagnosed with a first cancer of the head and neck
(EAR = 380.0), larynx (EAR = 266.3), oesophagus (EAR =
232.1), bladder (EAR = 121.7), lip (EAR = 74.3), kidney
(EAR = 66.4), lung (EAR = 62.0) or a chronic lymphatic
leukaemia (EAR = 50.2). Patients with a first prostate or
colorectal cancer presented a rather small excess risk of
SPC, with respective EAR values of 16.5 and 15.7. With
respect to female patients, the highest excess risks of SPC
were noted for first cancer of the larynx (EAR = 205.9),
head and neck (EAR = 194.8), oesophagus (EAR = 126.5),
vagina and vulva (EAR = 46.2) or an acute myeloid leukae-
mia (EAR = 42.7). Finally, patients with a first breast or
colorectal cancer presented somewhat lower excess risks
of SPC (EAR = 16.8 and 16.4, respectively).
Multivariate analyses
Among male and female patients, multivariate analyses
showed that age, year of diagnosis, follow-up and first
cancer site were often independently associated with
SIRs and EARs (Table 3). Compared with the second
year of follow-up, the EAR for more than 10 years of
follow-up was not significantly changed among males
(EAR ratio 0.87 95% IC, 0.71-1.07) but was increased
among females (EAR ratio 1.83 95% IC, 1.28-2.62). Inter-
estingly, this trend was hidden (or even slightly inverted
among males) when considering SIR values, due to the
increase of expected rates of cancer with attained age
during patient follow-up. These results also show that
patients with a first cancer diagnosed at 55 to 64 years-
old presented the highest excess risk of SPC. The risk of
SPC varied widely across first cancer sites (p < .001) but
detailed results are not shown, as the clinical relevance
of SIR and EAR ratios across patients with different
types of first cancer may be questionable. It should be
noted that, although the adjustment on cancer registry
showed some heterogeneity between registries (p < .001),
this adjustment did not upset the results presented in
Table 3 (results not shown).
Estimates by site of first and second cancer
Finally, Tables 4 and 5 detail risk estimates of SPC by
site of first and second primary cancer, with significant
EAR values superior or equal to 3.0 per 10,000 PYR
among males and 2.5 among females.
There were consistent and reciprocal associations be-
tween cancer of the head and neck, oesophagus, larynx and
lung. Bi-directional risks between lung and bladder cancers
were found. Bladder cancers were more frequent after a
first head and neck, oesophagus, larynx and kidney cancer.
There were significant associations between cancers of
the upper and lower digestive tract (head and neck,
oesophagus and colorectum). Among women, there was a
bidirectional association between breast and corpus uteri
cancers. Among men, patients with a first thyroid cancer
presented an increased risk of prostate cancer. There was
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an association between colorectal and bladder cancers in
men and between colorectal and corpus uteri cancer in
women. Patients with a first urological cancer (bladder,
kidney) presented a dramatically increased risk of prostate
SPC. Finally, patients presented an increased risk of lung
cancer after Hodgkin’s lymphoma among males, kidney
cancer after testicular cancer, colorectal or bladder cancer
after prostate cancer or cervical cancer.
Discussion
Main findings of this study
Firstly, French cancer survivors face a 36% increased risk
of SPC relative to the overall population without cancer
(SIR = 1.36). This risk is markedly high compared with
published estimates for Denmark (SIR = 0.91), Italy (0.93),
Finland (1.12), US (1.14), Vaud Canton, Switzerland (1.2),
Osaka Prefecture, Japan (1.21) and Queensland, Australia
(1.27) [4-10]. A strong argument that can be put forward
to explain this singular position of France is the particu-
larly high alcohol and tobacco consumption among male
adults in France. Indeed, although alcohol consumption
decreased in France from 25.0 to 13.7 l of pure alcohol per
capita between 1961 and 2004, this consumption remains
still high compared with the US consumption level of
about 9.4 l per capita over the same period [26]. In
addition, estimated age-standardized prevalence of current
smoking among male adults was of 36% in 2006 in France,
compared with 25% in the US [27]. Finally, in this cohort
of French survivors, tobacco and/or alcohol-related cancer
sites accounted for more than 50% of the total excess SPC,
compared with 35% in the US, as estimated by the Surveil-
lance, Epidemiology, and End Results (SEER) Program [4].
Secondly, multivariate analyses showed that most pa-
tient characteristics were independently associated with
SIRs and EARs, and that the EAR of SPC remained ele-
vated during patient follow-up. Although previous studies
stressed the slightly decreasing trend of SIRs with follow-
up [4], the elevated level of the EARs of SPC during
follow-up has never been clearly identified, due primarily
to the concurrent increase of the expected rates of cancer
with attained age. The effect of follow-up on SPC risk may
be the result of two distinct reverse effects; on the one
hand the extension of carcinogen exposure after first can-
cer diagnosis strengthens the risk of SPC and, on the other
hand, the progressive selection through cancer survival of
patients with a more favorable morbidity profile lowers
the risk of SPC. Pancreatic cancer is an extreme example
of this progressive selection of patients through survival,
pancreatic cancer survivors being significantly “protected”
against SPC compared with the general population with-
out cancer (SIR = 0.67 in our cohort). This may explain
the apparent contradictory results observed among men
and women in our study as, considering that survival is
often worse among men compared to women in France
Table 1 Risk of SPCa by gender, age, year of first cancer diagnosis and follow-up, France 1989–2004 (N = 289,967)
O E PYR SIR (95% CI) EARb (95% CI)
All patients 21,226 15,555.59 1,440,960 1.36 (1.35-1.38) 39.4 (37.4-41.3)
Gender Male 14,555 10,514.87 689,115 1.38 (1.36-1.41) 58.6 (55.2-62.1)
Female 6,671 5,040.73 751,845 1.32 (1.29-1.36) 21.7 (19.6-23.8)
Age at first cancer diagnosis ≤ 44 y 909 424.88 210,515 2.14 (2.00-2.28) 23.0 (20.2-25.9)
45 y-54 y 2,592 1,270.67 236,678 2.04 (1.96-2.12) 55.8 (51.7-60.1)
55 y-64 y 5,284 3,500.56 334,536 1.51 (1.47-1.55) 53.3 (49.1-57.6)
65 y-74 y 7,772 6,235.67 406,356 1.25 (1.22-1.27) 37.8 (33.6-42.1)
≥ 75 4,669 4,123.81 252,874 1.13 (1.10-1.17) 21.6 (16.3-26.9)
Year of first cancer diagnosis 1989-1994 7,512 5,406.49 517,048 1.39 (1.36-1.42) 40.7 (37.5-44.0)
1995-1999 7,679 5,634.00 520,856 1.36 (1.33-1.39) 39.3 (36.0-42.6)
2000-2004 6,035 4,515.10 403,057 1.34 (1.30-1.37) 37.7 (34.0-41.5)
Follow-up ≥ 2 m- < 1 y 3,170 2,280.81 213,502 1.39 (1.34-1.44) 41.6 (36.5-46.9)
≥ 1 y- < 2 y 3,034 2,229.98 210,970 1.36 (1.31-1.41) 38.1 (33.0-43.3)
≥ 2 y- < 4 y 4,983 3,665.14 343,730 1.36 (1.32-1.40) 38.3 (34.3-42.4)
≥ 4 y- < 6 y 3,504 2,614.81 241,999 1.34 (1.30-1.39) 36.7 (32.0-41.6)
≥ 6 y- < 8 y 2,522 1,815.96 166,357 1.39 (1.34-1.44) 42.4 (36.6-48.5)
≥ 8 y- < 10 y 1,664 1,239.15 112,267 1.34 (1.28-1.41) 37.8 (30.8-45.1)
≥ 10 y 2,349 1,709.75 152,135 1.37 (1.32-1.43) 42.0 (35.8-48.4)
SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval;
m, months; y, years.
aExcluding SPC occurring in the same subsite as the first primary cancer.
bNumber of excess cancers per 10,000 person-years at risk.
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Table 2 Risk of SPCa by gender and first cancer site, France 1989–2004 (N = 289,967)
Males Females
(N = 160, 807) (N = 129,160)
First cancer site O E PYR SIR EARb (95% CI) O E PYR SIR EARb (95% CI)
Lip 111 80.66 4,081 1.38* 74.3* (26.1-129.9) 13 8.44 806 1.54 56.6 (−18.9-171.2)
Tongue and lingual tonsil 329 90.84 6,794 3.62* 350.5* (299.6-405.8) 41 15.99 1,886 2.56* 132.6* (71.2-210.2)
Oral cavity 536 129.77 10,034 4.13* 404.9* (360.6-452.0) 83 23.36 2,863 3.55* 208.3* (149.3-277.8)
Salivary glands 29 20.45 1,480 1.42 57.8 (−7.0-143.3) 14 12.38 1,569 1.13 10.3 (−30.1-70.8)
Oropharynx 550 129.86 10,157 4.24* 413.7* (369.3-460.9) 52 14.54 1,813 3.58* 206.6* (134.0-295.9)
Nasopharynx 13 12.90 1,223 1.01 0.8 (−49.0-76.2) 8 3.33 535 2.41* 87.4* (2.2-232.6)
Hypopharynx 496 129.23 9,334 3.84* 392.9* (347.2-441.8) 27 4.40 577 6.13* 391.8* (232.1-604.9)
Head and neckc 1,981 509.07 38,731 3.89* 380.0* (357.8-403.1) 214 62.40 7,781 3.43* 194.8* (159.2-234.3)
Oesophagus 290 119.03 7,367 2.44* 232.1* (188.1-280.1) 27 11.27 1,244 2.40* 126.5* (52.4-225.2)
Stomach 240 233.16 12,773 1.03 5.4 (−17.7-30.7) 87 83.55 8,739 1.04 3.9 (−15.9-27.2)
Small intestine 32 31.37 1,848 1.02 3.4 (−51.4-74.7) 15 15.39 1,716 0.97 −2.3 (−40.8-54.5)
Colorectum 1,996 1,843.60 97,268 1.08* 15.7* (6.8-24.9) 935 792.53 87,123 1.18* 16.4* (9.6-23.5)
Colon 1,185 1,060.19 55,504 1.12* 22.5* (10.5-35.0) 590 491.42 54,649 1.20* 18.0* (9.5-27.1)
Rectum 810 783.28 41,747 1.03 6.4 (−6.7-20.2) 344 300.88 32,443 1.14* 13.3* (2.4-25.1)
Liver, primary 135 120.50 6,749 1.12 21.5 (−10.8-58.2) 23 13.82 1,709 1.66* 53.7* (4.4-121.1)
Gallbladder and biliary tract 30 38.16 1,950 0.79 −41.9 (−91.9-23.9) 31 24.89 2,463 1.25 24.8 (−15.5-77.6)
Pancreas 33 49.39 2,948 0.67* −55.6* (−90.5–10.3) 25 23.53 2,730 1.06 5.4 (−27.0-49.0)
Nasal cavities and sinuses 50 42.29 2,430 1.18 31.7 (−21.3-97.2) 3 5.90 650 0.51 −44.5 (−81.4-44.1)
Larynx 853 323.02 19,900 2.64* 266.3* (238.0-296.1) 58 16.93 1,995 3.43* 205.9* (135.9-291.0)
Lung, bronchus and trachea 855 599.96 41,161 1.43* 62.0* (48.3-76.4) 96 72.95 9,446 1.32* 24.4* (5.1-46.9)
Pleura 8 13.92 776 0.57 −76.2 (−134.9-23.8) 3 2.45 284 1.22 19.3 (−65.1-222.3)
Bone and cartilages 16 11.53 2,306 1.39 19.4 (−10.4-62.7) 11 8.25 2,087 1.33 13.2 (−13.2-54.8)
Soft tissue 67 55.74 4,965 1.20 22.7 (−7.7-59.1) 39 24.00 3,951 1.62* 38.0* (9.4-74.2)
Melanoma of skin 303 258.43 20,881 1.17* 21.3* (5.5-38.6) 288 208.83 32,126 1.38* 24.6* (14.6-35.6)
Breast 52 45.45 2,282 1.14 28.7 (−29.0-99.6) 2,476 1,885.48 351,434 1.31* 16.8* (14.1-19.6)
Cervix uteri - - - - - - 265 173.92 28,122 1.52* 32.4* (21.4-44.4)
Corpus uteri - - - - - - 511 370.65 41,147 1.38* 34.1* (23.6-45.4)
Ovary and uterine adnexa - - - - - - 189 168.03 22,829 1.12 9.2 (−2.2-21.9)
Vagina and vulva - - - - - - 59 39.51 4,219 1.49* 46.2* (12.8-86.7)
Prostate 3,880 3,500.52 230,582 1.11* 16.5* (11.2-21.8) - - - - - -
Testis 86 59.42 19,448 1.45* 13.7* (4.8-24.1) - - - - - -
Penis 43 42.20 2,303 1.02 3.5 (−48.1-68.3) - - - - - -
Bladder 1,192 729.56 38,002 1.63* 121.7* (104.1-140.0) 99 79.73 7,772 1.24* 24.8* (0.9-52.5)
Kidney 660 471.41 28,385 1.40* 66.4* (49.0-84.9) 198 149.07 17,327 1.33* 28.2* (12.9-45.3)
Melanoma of choroid 23 19.49 1,361 1.18 25.8 (−36.1-110.4) 14 12.84 1,465 1.09 7.9 (−35.4-72.7)
Brain 24 30.03 5,546 0.80 −10.9 (−26.4-10.2) 20 16.84 4,506 1.19 7.0 (−10.3-31.2)
Thyroid gland 88 62.22 7,369 1.41* 35.0* (11.3-62.7) 244 174.12 31,397 1.40* 22.3* (12.8-32.6)
Hodgkin’s disease 69 40.59 8,338 1.70* 34.1* (15.7-56.0) 38 22.16 6,930 1.72* 22.9* (6.8-43.3)
Non-Hodgkin’s lymphoma 448 348.23 26,008 1.29* 38.4* (22.8-55.1) 229 185.26 22,997 1.24* 19.0* (6.5-32.8)
Multiple myeloma 133 125.42 6,934 1.06 10.9 (−20.3-46.4) 73 66.51 6,946 1.10 9.3 (−13.4-36.4)
Leukaemia 377 323.41 22,217 1.17* 24.1* (7.4-42.1) 173 130.86 17,269 1.32* 24.4* (10.0-40.5)
Acute lymphatic leukaemia 4 3.21 3,064 1.25 2.6 (−7.0-23.0) 7 2.91 2,571 2.41 15.9 (−0.4-44.8)
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[28], the higher selection of male patients with favorable
profile during follow-up may have outweighed the
strengthening effect of the extension of carcinogen expos-
ure on the risk of SPC.
Patterns of first and second primary cancers
To date, different explanations have been put forward in
the literature to explain the specific patterns of first and
second primary cancers among cancer survivors. These in-
clude high tobacco and/or alcohol consumption, hormonal
and nutritional factors, exposure to virus and immunosup-
pression, genetic predisposition, increased site-specific
medical surveillance, late adverse effects of first cancer
treatments and interactions among these factors [4,5,15].
High tobacco and/or alcohol consumption
We confirmed consistent and reciprocal associations be-
tween cancer of the head and neck, oesophagus, larynx
and lung related to high tobacco and alcohol exposure
[4,25,29-31]. Other cancers that may be related to a high
tobacco and/or alcohol consumption include those of the
bladder, lip, stomach, liver, pancreas, kidney, cervix uteri,
colon and rectum. According to the concept of “field can-
cerization”, factors such as an exposure to carcinogens
induce a field of mucosa more susceptible to tumor
Table 2 Risk of SPCa by gender and first cancer site, France 1989–2004 (N = 289,967) (Continued)
Chronic lymphatic leukaemia 276 219.48 11,261 1.26* 50.2* (22.1-80.9) 123 91.97 9,091 1.34* 34.1* (11.3-60.3)
Acute myeloid leukaemia 21 23.63 2,585 0.89 −10.2 (−41.2-32.8) 23 12.37 2,491 1.86* 42.7* (8.8-88.9)
Chronic myeloid leukaemia 43 47.36 3,291 0.91 −13.3 (−49.4-32.1) 14 16.78 2,234 0.83 −12.4 (−40.9-30.0)
Other sitesd 542 412.95 25,949 1.31* 49.7* (32.5-68.1) 211 186.09 22,084 1.13 11.3 (−1.2-25.1)
All sitesd 14,555 10,514.87 689,115 1.38* 58.6* (55.2-62.1) 6,671 5,040.73 751,845 1.32* 21.7* (19.6-23.8)
SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
aExcluding SPC occurring in the same subsite as the first primary cancer.
bNumber of excess cancers per 10,000 person-years at risk.
cHead and neck site includes tongue and lingual tonsil, oral cavity, oropharynx, nasopharynx, hypopharynx and other oral cavity and pharynx.
dExcluding non-melanoma skin cancer.
*P < .05.
Table 3 Multivariate Poisson regression models of SPC riska by gender, France 1989–2004 (N = 289,967)
Males Females
(N = 160,807) (N = 129,160)
Ratio of SIRs P Ratio of EARs P Ratio of SIRs P Ratio of EARs P
(95% CI) (95% CI) (95% CI) (95% CI)
Age at first cancer diagnosis ≤ 44 y 1.98 (1.78-2.20) <.001 0.63 (0.54-0.75) <.001 1.27 (1.15-1.41) <.001 0.54 (0.40-0.72) <.001
45 y-54 y 1.49 (1.41-1.59) 0.93 (0.84-1.04) 1.11 (1.03-1.20) 0.90 (0.72-1.13)
55 y-64 y 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
65 y-74 y 0.86 (0.82-0.89) 0.88 (0.78-1.00) 0.93 (0.87-0.99) 0.89 (0.69-1.14)
≥ 75 0.81 (0.77-0.85) 0.67 (0.53-0.84) 0.83 (0.77-0.89) 0.51 (0.32-0.81)
Year of first cancer diagnosis 1989-1994 1.00 (ref) .271 1.00 (ref) .037 1.00 (ref) .003 1.00 (ref) <.001
1995-1999 0.97 (0.93-1.01) 0.88 (0.79-0.97) 1.10 (1.04-1.17) 1.48 (1.19-1.84)
2000-2004 0.99 (0.95-1.03) 0.92 (0.82-1.04) 1.10 (1.03-1.18) 1.44 (1.10-1.89)
Follow-up ≥ 2 m- < 1 y 1.00 (0.95-1.06) <.001 0.82 (0.71-0.95) .037 1.05 (0.96-1.16) .284 0.93 (0.62-1.33) .006
≥ 1 y- < 2 y 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
≥ 2 y- < 4 y 0.99 (0.94-1.05) 1.02 (0.90-1.17) 1.02 (0.94-1.11) 1.03 (0.76-1.40)
≥ 4 y- < 6 y 0.96 (0.90-1.01) 0.96 (0.83-1.12) 1.00 (0.92-1.10) 1.07 (0.76-1.49)
≥ 6 y- < 8 y 0.95 (0.89-1.01) 1.01 (0.85-1.20) 1.07 (0.97-1.18) 1.41 (1.01-1.97)
≥ 8 y- < 10 y 0.90 (0.83-0.97) 0.90 (0.73-1.11) 1.00 (0.90-1.12) 1.31 (0.89-1.94)
≥ 10 y 0.82 (0.76-0.88) 0.87 (0.71-1.07) 1.10 (1.00-1.22) 1.83 (1.28-2.62)
First cancer site b <.001 b <.001 b <.001 b <.001
SPC, second primary cancer; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval; ref, reference category.
aExcluding SPC occurring in the same subsite as the first primary cancer.
bDetailed results not shown.
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Table 4 Risk of SPC by first and second cancer site among male patients, France 1989–2004 (N = 160,807)
First cancer site Second cancer site O E PYR SIRa EARa,b (95% CI)
Lip Lung, bronchus and trachea 27 9.52 4,081 2.84 42.8 (20.3-72.9)
Oesophagus 7 1.79 3.91 12.8 (2.5-31.0)
Head and neck Lung, bronchus and trachea 663 76.15 38,731 8.71 151.5 (138.7-165.1)
Head and neckc 405 24.54 16.50 98.2 (88.3-108.9)
Oesophagus 269 13.79 19.51 65.9 (57.8-74.7)
Larynx 76 10.74 7.07 16.8 (12.7-21.8)
Colorectum 109 60.09 1.81 12.6 (7.6-18.4)
Liver, primary 62 17.04 3.64 11.6 (7.9-16.1)
Bladder 53 24.13 2.20 7.5 (4.0-11.7)
Kidney 35 17.32 2.02 4.6 (1.8-8.1)
Pancreas 26 11.03 2.36 3.9 (1.5-7.0)
Stomach 29 14.27 2.03 3.8 (1.3-7.1)
Oesophagus Head and neck 92 6.29 7,367 14.63 116.3 (92.1-144.6)
Lung, bronchus and trachea 71 16.70 4.25 73.7 (52.6-98.9)
Larynx 16 2.25 7.11 18.7 (9.4-32.2)
Colorectum 25 14.51 1.72 14.2 (2.3-30.4)
Stomach 10 3.72 2.69 8.5 (1.5-19.9)
Bladder 12 5.96 2.01 8.2 (0.3-20.4)
Colorectum Colorectumc 174 119.63 97,268 1.45 5.6 (3.0-8.5)
Lung, bronchus and trachea 279 240.30 1.16 4.0 (0.7-7.5)
Bladder 136 104.92 1.30 3.2 (0.9-5.8)
Larynx Lung, bronchus and trachea 310 44.71 19,900 6.93 133.3 (116.5-151.7)
Head and neck 138 15.78 8.75 61.4 (50.3-74.0)
Oesophagus 64 7.59 8.43 28.3 (21.0-37.3)
Bladder 46 16.25 2.83 15.0 (8.8-22.7)
Colorectum 62 39.40 1.57 11.4 (4.1-20.1)
Liver, primary 22 10.72 2.05 5.7 (1.5-11.4)
Stomach 19 9.27 2.05 4.9 (1.1-10.3)
Pancreas 14 6.96 2.01 3.5 (0.3-8.3)
Lung, bronchus and trachea Head and neck 127 31.83 41,162 3.99 23.1 (18.0-29.0)
Bladder 105 34.29 3.06 17.2 (12.5-22.5)
Oesophagus 55 15.65 3.51 9.6 (6.3-13.6)
Colorectum 121 84.25 1.44 8.9 (3.9-14.7)
Larynx 45 12.08 3.73 8.0 (5.0-11.7)
Kidney 45 21.47 2.10 5.7 (2.8-9.4)
Leukaemia 30 16.07 1.87 3.4 (1.0-6.5)
Melanoma of skin Leukaemia 19 6.22 20,881 3.06 6.1 (2.5-11.2)
Prostate Colorectum 830 692.73 230,582 1.20 6.0 (3.5-8.5)
Bladder 406 291.02 1.40 5.0 (3.3-6.8)
Testis Kidney 10 2.38 19,448 4.20 3.9 (1.2-8.2)
Bladder Lung, bronchus and trachea 295 94.45 38,002 3.12 52.8 (44.2-62.2)
Prostate 398 257.66 1.54 36.9 (26.9-47.7)
Head and neck 55 27.02 2.04 7.4 (3.8-11.7)
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formation and, due to the common conduit connecting the
upper aero-digestive tract, this is believed to elevate epithe-
lial cancer risk through the head and neck, lung and
oesophagus [31-33]. These associations, although well-
recognized in the literature, were strikingly pronounced in
our dataset. For instance, among male patients with a head
and neck cancer, respective EAR of lung, head and neck
and oesophagus SPC were 151.5, 98.2 and 65.9 per 10,000
PYR, while EAR estimates provided by the SEER Program
were 59.8, 75.2 and 14.2. These stronger associations may
be a consequence of the higher exposure to alcohol (de-
crease in alcohol consumption from 25.0 to 13.7 l of pure
alcohol per capita between 1961 and 2004 in France com-
pared with 9.4 l over the same period in the US) and to-
bacco (prevalence of current smoking among males of 36%
in France, compared with 25% in the US in 2006) in our
cohort [26,27].
Although there is growing evidence about the adverse ef-
fects of persistent tobacco smoking on SPC risk, treatment
effectiveness and survival, up to one-third to one-half of pa-
tients continue to smoke after diagnosis or relapse after ini-
tial quit attempts, depending on tumor site and duration of
follow-up [34]. In particular, among patients with a head
and neck cancer, persistent tobacco smoking and alcohol
consumption following index cancer diagnosis has been
reported to range from 30 to 40% and 34 to 44%, respect-
ively [35]. Continued tobacco smoking and/or alcohol
drinking after treatment have been estimated to be re-
sponsible for one-third of the SPCs of patients with an
index head and neck cancer [36]. Finally, it appears that
cancer diagnosis is underused as a teachable moment for
smoking cessation and that more research is needed to
empirically test and adapt smoking and alcohol drinking
cessation interventions for cancer patients [1,34,37].
Hormonal and nutritional factors
Identified hormonal-related cancers in the literature include
breast, prostate, endometrium, testis, ovary, thyroid and
osteosarcoma [38]. In our cohort, we confirmed among
women a bidirectional association between breast and cor-
pus uteri [4,9]. Among men, we only found a unidirectional
association between thyroid and prostate cancer [4].
Concerning nutritional factors, higher body-mass index
(BMI) is strongly associated with oesophageal adenocarcin-
oma, thyroid, colon and rectum cancers in men, and endo-
metrial, gallbladder, oesophageal adenocarcinoma and renal
cancers in women [39]. To date, the main mechanisms pro-
posed to explain these associations involve hormonal sys-
tems interlinked through insulin [39]. Although data about
BMI were not available, it is likely that overweight and
obesity played a role in the associations between cancers of
the upper and lower digestive tract (head and neck,
oesophagus and colorectum) observed in our cohort, as re-
ported in a previous study among colorectal cancer patients
performed in the French region of Isère [40]. Leaving to
one side tobacco and alcohol consumption, low intake of
fruits and vegetables may also have contributed to the ex-
cess risk of SPC observed in the upper and lower digestive
tract, as previously reported [4].
Table 4 Risk of SPC by first and second cancer site among male patients, France 1989–2004 (N = 160,807) (Continued)
Larynx 28 10.96 2.55 4.5 (2.0-7.8)
Stomach 38 23.71 1.60 3.8 (0.8-7.5)
Kidney Prostate 269 162.00 28,385 1.66 37.7 (26.7-49.7)
Bladder 39 24.55 1.59 5.1 (1.1-10.1)
Thyroid gland Prostate 34 20.08 7,369 1.69 18.9 (4.7-37.2)
Leukaemia 5 1.50 3.33 4.7 (0.1-13.8)
Hodgkin's disease Lung, bronchus and trachea 23 5.72 8,338 4.02 20.7 (10.6-34.5)
Non-Hodgkin’s lymphoma 6 1.33 4.50 5.6 (1.0-14.1)
Oesophagus 4 0.93 4.29 3.7 (0.2-11.2)
Non-Hodgkin’s lymphoma Lung, bronchus and trachea 76 46.84 26,008 1.62 11.2 (5.0-18.6)
Leukaemia 21 8.50 2.47 4.8 (1.7-9.1)
Bladder 30 17.70 1.70 4.7 (1.0-9.7)
Stomach 18 10.21 1.76 3.0 (0.2-7.0)
Chronic lymphatic leukaemia Lung, bronchus and trachea 56 27.69 11,261 2.02 25.1 (13.0-40.0)
Colorectum 41 27.78 1.48 11.7 (1.5-24.7)
Hodgkin’s disease 4 0.39 10.26 3.2 (0.6-8.7)
SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
aAll P < .05.
bNumber of excess cancers per 10,000 person-years at risk.
cSPC occurring in a different subsite as the first primary cancer.
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Table 5 Risk of SPC by first and second cancer site among female patients, France 1989–2004 (N = 129,160)
First cancer site Second cancer site O E PYR SIRa EARa,b (95% CI)
Head and neck Head and neckc 57 0.61 7,781 93.83 72.5 (54.7-94.1)
Lung, bronchus and trachea 51 2.71 18.81 62.1 (45.3-82.7)
Oesophagus 20 0.41 49.33 25.2 (15.2-39.2)
Liver, primary 5 0.69 7.25 5.5 (1.2-14.1)
Oesophagus Head and neck 10 0.14 1,244 71.04 79.3 (37.4-146.7)
Colorectum Breast 297 246.36 87,123 1.21 5.8 (2.0-9.9)
Colorectumc 98 67.48 1.45 3.5 (1.4-6.0)
Corpus uteri 66 41.93 1.57 2.8 (1.0-4.8)
Liver, primary Lung, bronchus and trachea 5 0.61 1,709 8.13 25.7 (5.8-64.7)
Non-Hodgkin’s lymphoma 3 0.53 5.62 14.4 (0.4-48.2)
Soft tissue 2 0.06 32.96 11.3 (1.0-41.9)
Larynx Lung, bronchus and trachea 19 0.74 1,995 25.76 91.5 (53.6-145.0)
Head and neck 10 0.22 45.47 49.0 (22.9-91.1)
Oesophagus 3 0.11 26.70 14.5 (2.5-43.4)
Bladder 3 0.28 10.73 13.6 (1.6-42.5)
Lung, bronchus and trachea Head and neck 10 0.99 9,446 10.09 9.5 (4.0-18.4)
Bladder 6 1.18 5.11 5.1 (1.1-12.6)
Oesophagus 3 0.47 6.41 2.7 (0.1-8.8)
Soft tissue Ovary and uterine adnexa 4 0.86 3,951 4.68 8.0 (0.6-23.8)
Melanoma of skin Breast 98 75.05 32,127 1.31 7.1 (1.4-13.8)
Kidney 15 5.32 2.82 3.0 (1.0-6.0)
Breast Corpus uteri 358 147.83 351,434 2.42 6.0 (5.0-7.1)
Cervix uteri Lung, bronchus and trachea 34 7.66 28,122 4.44 9.4 (5.6-14.2)
Colorectum 40 22.60 1.77 6.2 (2.1-11.3)
Vagina and vulva 10 1.28 7.82 3.1 (1.2-6.1)
Leukaemia 12 4.17 2.88 2.8 (0.7-6.0)
Bladder 10 2.45 4.08 2.7 (0.8-5.7)
Corpus uteri Breast 174 120.03 41,147 1.45 13.1 (7.1-19.9)
Colorectum 106 60.33 1.76 11.1 (6.4-16.5)
Lung, bronchus and trachea 34 17.06 1.99 4.1 (1.6-7.4)
Vagina and vulva Cervix uteri 6 0.68 4,219 8.87 12.6 (3.6-29.4)
Bladder 4 0.88 4.53 7.4 (0.5-22.2)
Head and neck 3 0.47 6.37 6.0 (0.3-19.7)
Kidney Breast 62 46.58 17,327 1.33 8.9 (0.6-19.0)
Lung, bronchus and trachea 16 6.61 2.42 5.4 (1.5-11.2)
Leukaemia 11 4.07 2.70 4.0 (0.8-9.0)
Thyroid gland 8 2.70 2.96 3.1 (0.4-7.5)
Thyroid gland Leukaemia 13 3.95 31,397 3.29 2.9 (0.9-5.8)
Hodgkin’s disease Leukaemia 5 0.50 6,930 10.05 6.5 (1.6-16.1)
Non-Hodgkin’s lymphoma 5 0.73 6.89 6.2 (1.3-15.8)
Lung, bronchus and trachea 4 0.97 4.14 4.4 (0.2-13.4)
Jégu et al. BMC Cancer 2014, 14:94 Page 9 of 14
http://www.biomedcentral.com/1471-2407/14/94
Exposure to virus and immunosuppression
It is established that Epstein-Barr virus, human papilloma
virus (HPV), hepatitis C virus, hepatitis B virus, human
herpes virus 8 and human T-cell leukemia virus are causa-
tive agents of human cancer [41] and may have contrib-
uted to certain associations of cancers. For example, in
our cohort, 12.5% of colorectal SPCs after a first cervix
uteri cancer were anal tumors, which could be a conse-
quence of HPV infections and underlying immunologic
defects. Oropharyngeal squamous cell cancer of the lin-
gual and palatine tonsils recorded in our cohort may also
be related to HPV infection [42]. Moreover, human im-
munodeficiency virus or alteration of the regulation and
inflammation systems may also have contributed to cer-
tain excess cancers observed after first lymphoproliferative
tumors [4].
Genetic predisposition
Cancer survivors with a family history of cancer may be at
high risk of SPC, with most common syndromes identified
to date including mutations in BRCA1 and BRCA2 genes
and Lynch syndrome [15]. Carriers of BRCA1 or BRCA 2
tumor suppressor gene mutations face a high lifetime risk
of breast and ovarian cancer, as well as a moderate in-
crease in the risk of pancreatic, uterine body and uterine
cervix cancers for BRCA1 [43], and malignant melanoma,
pancreatic, stomach, gallbladder and bile duct cancers for
BRCA 2 [44]. We retrieved no further evidence of these
associations in our population-based cohort, considering
that patients with an ovarian cancer did not present a sig-
nificantly increased risk of SPC, while an association was
only found between breast and corpus uteri cancer. This
may be explained by the low prevalence of these muta-
tions in the population. Indeed, Malone et al. reported a
respective prevalence of 2.4% and 2.3% for mutations of
BRCA1 and BRCA2 in a population-based study of breast
cancer in white and black American women aged 35 to 64
years [45].
Lynch syndrome, also called hereditary nonpolyposis
colorectal cancer, is due to a mutation in one of the DNA-
mismatch repair genes and is characterized by the devel-
opment of cancer of the colorectum, endometrium and,
less frequently, cancer of the small bowel, stomach, urin-
ary tract, ovaries and brain [46]. We effectively found an
association between colorectal and bladder cancers in
men and between colorectal and corpus uteri cancer in
women. However, considering the low prevalence of this
syndrome (1-5% of colorectal cancers) [46], it is unlikely
that such genetic predispositions have outweighed the
impact of tobacco and alcohol, hormonal and nutri-
tional factors.
Increased site-specific medical surveillance
We confirmed in our cohort that patients with a first
urological cancer (bladder, kidney) present an increased
risk of prostate SPC [5]. Although some prostate SPC
may have been discovered consecutive to a radical cysto-
prostatectomy for first bladder cancer treatment, it can-
not be excluded that a non-negligible part of these SPC
may have been diagnosed through repeated PSA testing
during follow-up.
Late adverse effects of first cancer treatments
Curtis et al. reported that, by contrast to children and
young adults, cancer therapy among older adults was
not associated with a substantial increase in subsequent
cancer risk [4]. Indeed, radiotherapy-associated cancers
include a long latency period of at least 5 to 10 years
and a tendency to arise within or at the edges of prior
treatment fields [15]. Association confirmed in our
study include lung cancer after Hodgkin’s lymphoma
[4,47,48], kidney cancer after testicular cancer [49],
colorectal or bladder cancer after prostate cancer [50]
or cervical cancer [51]. However, it should be noted
that, among US adults, the estimated proportion of
SPC attributable to radiotherapy was 8%, which finally
suggests that most of them are due to other factors,
such as lifestyle or genetics [52].
With respect to chemotherapy-related malignancies,
the use of alkylating agents or drugs binding to the en-
zyme DNA-topoisomerase II may have contributed to
subsequent leukemia after Hodgkin’s disease in women
and non-Hodgkin’s lymphoma in men reported in our
study [53]. Among breast cancer patients, hormonal
therapy (primarily tamoxifen) may have contributed to
the increase in the subsequent risk of uterine cancer ob-
served in our cohort [54].
Table 5 Risk of SPC by first and second cancer site among female patients, France 1989–2004 (N = 129,160) (Continued)
Non-Hodgkin’s lymphoma Stomach 12 5.02 22,997 2.39 3.0 (0.5-6.9)
Kidney 12 4.99 2.41 3.0 (0.5-6.9)
Chronic lymphatic leukaemia Breast 41 26.30 9,091 1.56 16.2 (3.4-32.3)
Acute myeloid leukaemia Ovary and uterine adnexa 3 0.48 2,491 6.26 10.1 (0.5-33.3)
SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
aAll P < .05.
bNumber of excess cancers per 10,000 person-years at risk.
cSPC occurring in a different subsite as the first primary cancer.
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Interactions among these factors
To date, few studies have enlightened the interactions be-
tween risk factors of SPC. The International Head and
Neck Cancer Epidemiology consortium reported that sim-
ultaneous exposure to tobacco and alcohol involved a
greater than multiplicative joint effect on the risk of head
and neck cancer [55]. Finally, smoking increases the risk
of radiotherapy-related or alkylating agent-related lung
SPC in patients treated for a Hodgkin’s disease [48,56].
Methodological considerations
Several methodological aspects of this analysis require spe-
cial attention. A first questionable point is the 2-month
delay used to define metachronous tumors. Although this
limit was consistent with the one used in most previous
population-based studies of this type [4-7,10], we per-
formed sensitivity analyses using a 6-month delay, which
provided very similar results (SIR = 1.35 and EAR= 38.3
versus SIR = 1.36 and EAR= 39.4, as reported in our study).
Secondly, we excluded patients with a synchronous
tumor. This is slightly different from the exclusion process
of synchronous cancers performed in other studies, where
patients with two synchronous cancers could be included,
with any subsequent cancer (i.e. third, forth, …) being con-
sidered as a new primary [4,5]. The impact of the inclusion
of patients with synchronous SPC may lead, by an anticipa-
tion of prevalence cases during the synchronous period, to:
– on the one hand, a decrease of the number of cases
that may have been observed in subsequent follow-
up periods or,
– on the other hand, to keeping patients who present
a particularly high carcinogenic exposition and thus
carry the highest risk of new malignancy.
We repeated our analysis by including the 4,053 pa-
tients (1.2%) with synchronous SPC and considered any
third cancer developed by these patients as a SPC. We
found respective SIR and EAR values of 1.37 and 40.0,
which shows that including patients with synchronous
cancer may have resulted in an only slight overesti-
mation of the risk of SPC.
A third questionable point may be the consideration of
the activity period of cancer registries and its impact on
cancer rank determination. Indeed, more recently estab-
lished registries may wrongly consider some SPC as first
cancers if the true first cancer diagnosis date is anterior to
the beginning of the registration period. In order to appre-
ciate the direction and the magnitude of this bias, we con-
ducted sensitivity analyses in Bas-Rhin, comparing overall
SPC risk estimates obtained over fictional registration pe-
riods beginning ten years (1979), five years (1984) and zero
years (1989) before the study period 1989–2007. We found
that, with respect to the ten-year period, SIRs were
overestimated by 0.1% and 0.6% for the five-year and zero-
year periods, respectively. In other words, considering
some SPC as first cancers leads to a small overestimation
of SPC risk by keeping patients with higher risk of new
malignancies evidenced by the presence of two cancers. In
our study, almost all cancer registries were established
from 1975 to 1983 (i.e. more than five years before 1989),
with the exception of Manche cancer registry, set up in
1994. Considering that cases from the Manche cancer
registry only represent 7.4% of our cohort, the overall mag-
nitude of this bias is very small.
Fourthly, new malignancies occurring among patients
who migrate from their original cancer registry geo-
graphic area may not have been recorded. According to
census data, the mean annual migration rate out of any
French administrative region (called “département”) was
estimated as 3.1% between 1999 and 2004, decreasing
with age from 6.9% to 1.2% for 20–29 and ≥ 60 years-old
people, respectively [57]. Considering that the mean age
at first cancer diagnosis is superior to 60 years in our co-
hort, it is reasonable to assume that this migration bias,
although more significant among young patients, would
not upset the overall results presented here. Moreover, a
recent study assessing this type of bias among US child-
hood cancer survivors found no evidence of an out-
migration bias in the incidence of SPCs in SEER [58].
Finally, we focused the analyses on the risk of SPC oc-
curring in a different subsite as the first primary cancer,
and this for two reasons. First, SPCs arising in the same
subsite of non-paired organs are scarce, mainly due to
surgical removal of the affected organ [4]. This is a well-
known issue while considering prostate cancer survi-
vors, as the high number of expected (E) SPC of the
prostate calculated in such an elderly population is
largely overestimated compared with the real number of
prostate SPC likely to occur among these patients. Sec-
ond, according to the common set of rules proposed
by the International Agency for Research on Cancer
(IARC), multiple primaries arising in the same site are
only to be recorded when the morphology belongs to
different groups [17]. For instance, among breast cancer
patients, the number of observed (O) subsequent breast
cancers may be underestimated as most of the new ma-
lignancies of the breast will not be recorded because of
similar morphology. Ultimately, these respective overes-
timations of E and underestimations of O would both
have led to underestimated SIR and EAR values, which
rendered it advisable to exclude cancers occurring in
the same subsite from SPC risks calculations. It should
be noted that such exclusion was also performed in re-
cent studies about SPC incidence performed in the US
(an “all excluding same site” estimate of the risk of sub-
sequent cancers is provided) and in the Japanese region
of Osaka [4,9].
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Future directions
Considering the dramatically high risk of tobacco and
alcohol-related SPC in France, the results of this study will
be of immediate use in a public health perspective for the
preparation of the third French Cancer Plan. In particular,
strengthening the measures to control tobacco and alcohol
epidemics in France and promoting research about smok-
ing cessation and alcohol abstinence interventions adapted
to cancer survivors should be considered.
The use of multivariate models to analyze SPC incidence
with cancer registry data will provide new research per-
spectives. Indeed, for specific sites of first cancer which
present a particularly high risk of SPC identified in this
overall analysis, further analyses are in progress in the
framework of the K2-France study to provide detailed re-
sults about follow-up strategy and etiological research
questions.
Furthermore, as there are no individual-specific risk pre-
diction tools akin to those used for selected primary can-
cers [15], the use of the multivariate approach described
in this paper will allow a determination of which clinical
characteristics are associated with the risk of SPC for a
given site of first cancer, enabling the construction of a tai-
lored risk prediction tool. Such a tool will facilitate SPC
individualized risk assessment by clinicians and contribute
to the implementation of optimal prevention and early de-
tection strategies.
Conclusions
French cancer survivors face a dramatically increased
risk of SPC which is probably related to the high rate of
tobacco and alcohol consumption in France. Multivari-
ate modeling of SPC risk will facilitate the construction
of a tailored prediction tool to optimize SPC prevention
and early detection strategies.
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